Prognostic impact of circulating HER2 extracellular domain (ECD) in women with metastatic breast cancer.

被引：0
|
作者：
Zheng, Yabing [1 ]
Shao, Xiying [1 ]
Wang, Xiaojia [1 ]
Shi, Lei [1 ]
Huang, Yuan [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e22038
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
    Kurbacher, C. M.
    Quade, A.
    Eichler, C.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. R.
    CANCER RESEARCH, 2016, 76
  • [32] Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
    Beije, Nick
    Onstenk, Wendy
    Kraan, Jaco
    Sieuwerts, Anieta M.
    Hamberg, Paul
    Dirix, Luc Y.
    Brouwer, Anja
    de Jongh, Felix E.
    Jager, Agnes
    Seynaeve, Caroline M.
    Van, Ngoc M.
    Foekens, John A.
    Martens, John W. M.
    Sleijfer, Stefan
    NEOPLASIA, 2016, 18 (11): : 647 - 653
  • [33] ELEVATED SERUM LEVELS OF THE HER2 EXTRACELLULAR DOMAIN (ECD) IN PRIMARY BREAST CANCER (PBC) WITH HER2 OVEREXPRESSION PREDICT EARLY FAILURE OF ADJUVANT TRASTUZUMAB
    Thureau, S.
    Clatot, F.
    Laberge-Le-Couteulx, S.
    Baron, M.
    Basuyau, J. P.
    Blot, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 82 - 82
  • [34] Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine
    Kurbacher, C. M.
    Quade, A.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [35] HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
    Tse, Chantal
    Gauchez, Anne-Sophie
    Jacot, William
    Lamy, Pierre-Jean
    CANCER TREATMENT REVIEWS, 2012, 38 (02) : 133 - 142
  • [36] Comparison between HER2 extracellular domain in serum and HER2 overexpression in breast cancer tissue
    Zidan, J.
    Mzalbat, R.
    Svalb, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S142 - S142
  • [37] Comparison between HER2 extracellular domain in serum and HER2 overexpression in breast cancer tissue
    Zidan, J.
    Mzalbat, R.
    Shnaider, J.
    Sharabi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] HER2 alterations and prognostic implications in all subtypes of breast cancer.
    O'Keefe, Kaitlyn
    Elliott, Andrew
    Livasy, Chad
    Steiner, Meghan
    Kang, Irene
    Hoon, Dave S. B.
    Korn, Wolfgang Michael
    Walker, Phillip
    Radovich, Milan
    Pohlmann, Paula R.
    Swain, Sandra M.
    Tan, Antoinette R.
    Heeke, Arielle Lutterman
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with breast cancer.
    Criscitiello, Carmen
    Viale, Giuseppe
    Disalvatore, Davide
    Bagnardi, Vincenzo
    Fumagalli, Luca
    Gelao, Lucia
    Locatelli, Marzia Adelia
    Rotmensz, Nicole
    Goldhirsch, Aron
    Curigliano, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
    Nozawa, Kazuki
    Kusudo, Maho
    Kureyama, Nari
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
12345